Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nektar Therapeutics (Nektar) carries out discovery and development of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The companys technology platforms offer a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The companys products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs, and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics Key Recent Developments

May 10,2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018
Mar 01,2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results
Nov 22,2017: Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Companys Immuno-Oncology Pipeline
Nov 07,2017: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017
Sep 21,2017: Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Nektar Therapeutics - Key Facts 5
Nektar Therapeutics - Key Employees 6
Nektar Therapeutics - Key Employee Biographies 8
Nektar Therapeutics - Major Products and Services 10
Nektar Therapeutics - History 12
Nektar Therapeutics - Company Statement 15
Nektar Therapeutics - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 Company Analysis 18
Nektar Therapeutics - Business Description 18
Nektar Therapeutics - Corporate Strategy 19
Nektar Therapeutics - SWOT Analysis 20
SWOT Analysis - Overview 20
Nektar Therapeutics - Strengths 20
Nektar Therapeutics - Weaknesses 21
Nektar Therapeutics - Opportunities 22
Nektar Therapeutics - Threats 23
Nektar Therapeutics - Key Competitors 24
Section 3 Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 Companys Lifesciences Financial Deals and Alliances 31
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Nektar Therapeutics, Recent Deals Summary 33
Section 5 Companys Recent Developments 34
May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 34
Nov 22, 2017: Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Companys Immuno-Oncology Pipeline 37
Nov 07, 2017: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 38
Sep 21, 2017: Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member 40
Aug 08, 2017: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017 41
May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 42
May 03, 2017: Nektar Therapeutics appoints new head of clinical development for immunology program 44
Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 45
Section 6 Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51

List Of Tables

List of Tables
Nektar Therapeutics, Key Facts 5
Nektar Therapeutics, Key Employees 6
Nektar Therapeutics, Key Employee Biographies 8
Nektar Therapeutics, Major Products and Services 10
Nektar Therapeutics, History 12
Nektar Therapeutics, Other Locations 17
Nektar Therapeutics, Subsidiaries 17
Nektar Therapeutics, Key Competitors 24
Nektar Therapeutics, Ratios based on current share price 25
Nektar Therapeutics, Annual Ratios 26
Nektar Therapeutics, Annual Ratios (Cont...1) 27
Nektar Therapeutics, Interim Ratios 29
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Nektar Therapeutics, Recent Deals Summary 33
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List Of Figures

List of Figures
Nektar Therapeutics, Performance Chart (2013 - 2017) 28
Nektar Therapeutics, Ratio Charts 30
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

Nektar Therapeutics (NKTR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Nektar Therapeutics (Nektar) carries out discovery and development of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The companys

USD 250 View Report

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

Nektar Therapeutics (NKTR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Nektar Therapeutics (Nektar) carries out discovery and development of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The companys

USD 250 View Report

Nektar Therapeutics Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Nektar Therapeutics Company Profile is a detailed strategic and analytical report on Nektar Therapeutics. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available